Inovio Pharmaceuticals (INO) Cash from Operations (2010 - 2026)

Inovio Pharmaceuticals has disclosed Cash from Operations across 17 years of filings, most recently posting -$18.0 million for Q2 2026.

• In Q2 2026, Cash from Operations rose 13.28% year-over-year to -$18.0 million; the TTM figure through Jun 2026 stood at -$80.6 million (up 14.99% YoY), while the FY2025 annual figure was -$88.6 million, up 14.84% from the prior year.
• Cash from Operations came in at -$18.0 million for Q2 2026 at Inovio Pharmaceuticals, up from -$21.6 million in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of -$18.0 million in Q2 2026 to a low of -$67.5 million in Q3 2022.
• Average Cash from Operations over 5 years is -$31.8 million, with a median of -$27.8 million recorded in 2024.
• Year-over-year, Cash from Operations tumbled 45.12% in 2022 and soared 56.85% in 2023.
• Over 5 years, Cash from Operations stood at -$36.3 million in 2022, then rose by 27.69% to -$26.3 million in 2023, then rose by 25.16% to -$19.7 million in 2024, then advanced by 1.49% to -$19.4 million in 2025, then grew by 6.83% to -$18.0 million in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were -$18.0 million in Q2 2026, -$21.6 million in Q1 2026, and -$19.4 million in Q4 2025.